Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
38’s on deck. Looking good!
Agree. . It’s a good day. $IPIX.
Apparently I thought so. Any more questions?
Like does sitting upfront mean your sitting in the front row?
Right, What’s a 33% delta in the grand scheme of things.
Yes. I took that into consideration. I also took into consideration the fact the trial started so the clock has been ticking for an unspecified period of time. I expect results as early as April, end of May at the latest.
Correct. 5 days total.
Hope all is well Keltoi.
Hound.
Ya, I’m a newbie at this.
2 month min. for results is more appropriate. When did the study start?
I do agree final published results will take more time.
2-3 months till final results.
Lmao. 60 patients per arm dosed over a period of 3-5 days does not support your opinion.
Given the protocol design, we have 3 months minimum to wait for final results.
$IPIX issued a very well put together PR this morning regarding their COVID trial. Nice work Leo. Job well done!
Innovation Pharma Provides Study Details for Ongoing Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients
WAKEFIELD, MA – February 26, 2021 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provides additional study details for its ongoing Phase 2 clinical trial assessing Brilacidin as a novel therapeutic in hospitalized patients with COVID-19. Patients are being treated, with recruitment and enrollment progressing at trial sites.
Innovation Pharma is developing Brilacidin, a defensin-mimetic, under Fast Track designation from the U.S. Food and Drug Administration (FDA).
The Phase 2 Brilacidin for COVID-19 clinical trial is a randomized, double-blind, placebo-controlled, international, multi-center study with planned enrollment of ~120 subjects with moderate-to-severe COVID-19. Two treatment arms are enrolling patients—active and placebo, with ~60 patients per arm. The study protocol provides for 3 days of study drug administration.
Active Arm (Brilacidin): Standard of Care + daily Brilacidin IV infusion for 3 days
Control Arm (Placebo): Standard of Care + daily Saline IV infusion for 3 days
After an interim review, by an independent Data Monitoring Committee (DMC), dosing may be extended to 5 days.
The trial’s primary endpoint is time to sustained recovery through Day 29, using a clinical status ordinal scale based on that used in the series of National Institute of Allergy and Infectious Diseases (NIAID) Adaptive COVID-19 Treatment Trials (ACTTs). Additional endpoints include: in-hospital outcomes (e.g., duration of hospitalization, time to discharge), all-cause mortality, measurement of disease biomarkers (e.g., CRP, ferritin) and inflammation-related biomarkers (e.g., IL-1ß, IL-6, IL-10, total IL-18, TNF-a), changes to SARS-CoV-2 viral load, as well as other key measures.
The study protocol will be registered and posted on www.clinicaltrials.gov.
Brilacidin and COVID-19
Brilacidin, which has received FDA Fast Track designation for the potential treatment of COVID-19, is one of the few drugs targeting COVID-19 that has been tested in human trials (a total of 8) for other clinical indications, providing established safety and efficacy data on over 460 subjects, thereby potentially enabling it to rapidly help address the novel coronavirus crisis. Pre-clinical testing at independent laboratories supports Brilacidin’s antiviral ability to safely and potently inhibit SARS-CoV-2, and multiple strains of human coronaviruses (H-CoVs). In a human lung cell line against SARS-CoV-2, Brilacidin achieved a Selectivity Index of 426. A molecular screening study of 11,552 compounds also supports Brilacidin as a promising novel coronavirus treatment. Brilacidin antiviral research to date has been limited to laboratory-based experiments. Additional pre-clinical and clinical data support Brilacidin’s inhibition of IL-6, IL-1ß, TNF-a and other pro-inflammatory cytokines and chemokines, which have been identified as central drivers in the worsening prognoses of hospitalized COVID-19 patients. Brilacidin’s robust antimicrobial properties might also help to fight secondary bacterial infections, which can co-present in up to 20 percent of COVID-19 patients. Collectively, these data support Brilacidin as a unique 3-in-1 combination—antiviral, immuno/anti-inflammatory, and antimicrobial—COVID-19 therapeutic candidate, with pan-coronavirus treatment potential. The Company has initiated a randomized, placebo-controlled Phase 2 clinical trial of Brilacidin for treatment of COVID-19 in moderate-to-severe hospitalized patients. A peer-reviewed article in Viruses supporting Brilacidin’s COVID-19 treatment potential can be accessed at the link below.
Bakovic, A.; Risner, K.; Bhalla, N. (et al). Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture. Viruses 2021, 13, 271; https://doi.org/10.3390/v13020271
https://www.mdpi.com/1999-4915/13/2/271/
Global COVID-19 Cases and Mortality
An online tool tracking COVID-19 cases and mortality, both in the U.S. and globally, can be found on the Company’s website (http://www.ipharminc.com), and at the following link:
https://ipixcovid19tracker.com/
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious diseases, and dermatologic diseases. Brilacidin, a versatile compound with broad therapeutic potential, is in a new chemical class called defensin-mimetics. A Phase 2 trial of Brilacidin as an oral rinse for the prevention of Severe Oral Mucositis (SOM) in patients with Head and Neck Cancer met its primary and secondary endpoints, including reducing the incidence of SOM. The Company plans to advance Brilacidin oral rinse into Phase 3 development, subject to available financial resources. Positive results were also observed in a Phase 2 Proof-of-Concept trial treating patients locally with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS). Brilacidin for UP/UPS was licensed to Alfasigma S.p.A. in July 2019, who have recently completed a Phase 1 study with their formulation. A Phase 2b trial of Brilacidin showed a single intravenous dose of the drug delivered comparable outcomes to a seven-day dosing regimen of the FDA-approved blockbuster daptomycin in treating Acute Bacterial Skin and Skin Structure Infection. Brilacidin, based on promising in vitro antiviral activity against SARS-CoV-2, is being evaluated in a Phase 2 clinical trial as a potential treatment for COVID-19. Kevetrin is a novel anti-cancer drug shown to modulate p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations and has successfully completed a Phase 2 trial in Ovarian Cancer. More information is available on the Company website at www.IPharmInc.com.
“Pretty crap if you ask me.”
I didn’t.
“No way he doesnt PR a multinational trial start unless he is gagged for some reason.”
He just released the info in a quarterly report.
Trial in progress and we’re sitting in mid 30’s. Not a bad range for the time being.
When could the world population reach heard immunity?
Whoohoo! $IPIX COVID trial in US is underway!
“In February 2021, the clinical trial of Brilacidin for treating hospitalized patients with COVID-19 in the United States and Russia began with patients being recruited to the study."
https://www.sec.gov/Archives/edgar/data/1355250/000147793221000999/ipix_10q.htm
WOW! Huge NEWS! $IPIX
Protocol name
Double-blind, placebo-controlled, randomized, multicenter Phase II study to evaluate the efficacy and safety of Brilacidin in patients hospitalized with COVID-19
Therapeutic area
Anesthesiology and resuscitation, Infectious diseases, Oncology, Therapy (general), Surgery, Cardiology, Pulmonology, Toxicology
CI start and end date
12/17/2020 - 03/31/2021
RCT number and date
No. 705 dated 12/17/2020
CI organization
Innovation Pharmaceuticals Inc. (Innovation Pharmaceuticals Inc.)
Drug name
Brilacidin
Dosage form and dosage
solution for intravenous administration, 50 mg / ml
Cities
Barnaul, Kirovsk, Moscow, Nizhny Novgorod, Ryazan, St. Petersburg, Saratov, Yaroslavl
Developer country
USA
Organization involved by the drug developer
IPharma LLC, 143026, Moscow, the territory of the Skolkovo innovation center, st. Nobel, 7, Russia
CI phase
II
KI type
IMCI
The purpose of CI
assessment of the efficacy and safety of Brilacidin in patients hospitalized with COVID-19
Number of medical institutions
20
Number of patients
106
Where the research is done
one
KGBUZ "City Hospital No. 5, g. Barnaul "
Region
Altai region
Town
Barnaul
Researchers
Martynenko T.I.
2
GBUZ LO "Kirovskaya MB"
Region
Leningradskaya
Town
Kirovsk
Researchers
Klinov A.S
3
IKB No. 1
Region
Moscow city
Town
Moscow
Researchers
Nurmukhametova E.A.
four
GBUZ "GKB No. 52 DZM"
Region
Moscow city
Town
Moscow
Researchers
Fomina D.S
five
FSBI "Central Clinical Hospital with a Polyclinic"
Region
Moscow city
Town
Moscow
Researchers
Lomakin N.V.
6
GUZ GKB No. 15
Region
Moscow city
Town
Moscow
Researchers
Gordeev I.G.
7
FSBEI HE MGMSU them. A.I. Evdokimova, Ministry of Health of Russia
Region
Moscow city
Town
Moscow
Researchers
Vertkin A.L. , Rogova I.V.
8
GBUZ "NII SP named after N.V. Sklifosovsky Research Institute for Emergency Medicine "
Region
Moscow city
Town
Moscow
Researchers
Zhuravel S.V
9
FGAOU VO First MGMU im. THEM. Sechenov Moscow State Medical University (Sechenov University)
Region
Moscow city
Town
Moscow
Researchers
Moiseev S.V. , Smolyarchuk E.A.
ten
GUZ NO GKB No. 3 (NGTs)
Region
Nizhny Novgorod Region
Town
Nizhny Novgorod
Researchers
Makarova A.E
eleven
GBU RO "OKB"
Region
Ryazan Oblast
Town
Ryazan
Researchers
Ivanova A.Yu
12
SPb GBUZ "Nikolaevskaya hospital"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Nigrieva Y.N
thirteen
SPb GBUZ "City Mariinsky Hospital"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Mamonov A.G.
14
S-Pb GUZ "City Hospital No. 38 named after N. A. Semashko"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Popov A.V
15
SPb GBUZ "City Hospital No. 15"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Goloshchekin B.M
16
SPb GBUZ "City Pokrovskaya Hospital"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Khmelnitsky O.K
17
FGBOU VO Saratov State Medical University named after IN AND. Razumovsky Ministry of Health of Russia
Region
Saratov region
Town
Saratov
Researchers
Schwartz Yu.G
Lmao. Right!
WOW! Huge NEWS! $IPIX
Protocol name
Double-blind, placebo-controlled, randomized, multicenter Phase II study to evaluate the efficacy and safety of Brilacidin in patients hospitalized with COVID-19
Therapeutic area
Anesthesiology and resuscitation, Infectious diseases, Oncology, Therapy (general), Surgery, Cardiology, Pulmonology, Toxicology
CI start and end date
12/17/2020 - 03/31/2021
RCT number and date
No. 705 dated 12/17/2020
CI organization
Innovation Pharmaceuticals Inc. (Innovation Pharmaceuticals Inc.)
Drug name
Brilacidin
Dosage form and dosage
solution for intravenous administration, 50 mg / ml
Cities
Barnaul, Kirovsk, Moscow, Nizhny Novgorod, Ryazan, St. Petersburg, Saratov, Yaroslavl
Developer country
USA
Organization involved by the drug developer
IPharma LLC, 143026, Moscow, the territory of the Skolkovo innovation center, st. Nobel, 7, Russia
CI phase
II
KI type
IMCI
The purpose of CI
assessment of the efficacy and safety of Brilacidin in patients hospitalized with COVID-19
Number of medical institutions
20
Number of patients
106
Where the research is done
one
KGBUZ "City Hospital No. 5, g. Barnaul "
Region
Altai region
Town
Barnaul
Researchers
Martynenko T.I.
2
GBUZ LO "Kirovskaya MB"
Region
Leningradskaya
Town
Kirovsk
Researchers
Klinov A.S
3
IKB No. 1
Region
Moscow city
Town
Moscow
Researchers
Nurmukhametova E.A.
four
GBUZ "GKB No. 52 DZM"
Region
Moscow city
Town
Moscow
Researchers
Fomina D.S
five
FSBI "Central Clinical Hospital with a Polyclinic"
Region
Moscow city
Town
Moscow
Researchers
Lomakin N.V.
6
GUZ GKB No. 15
Region
Moscow city
Town
Moscow
Researchers
Gordeev I.G.
7
FSBEI HE MGMSU them. A.I. Evdokimova, Ministry of Health of Russia
Region
Moscow city
Town
Moscow
Researchers
Vertkin A.L. , Rogova I.V.
8
GBUZ "NII SP named after N.V. Sklifosovsky Research Institute for Emergency Medicine "
Region
Moscow city
Town
Moscow
Researchers
Zhuravel S.V
9
FGAOU VO First MGMU im. THEM. Sechenov Moscow State Medical University (Sechenov University)
Region
Moscow city
Town
Moscow
Researchers
Moiseev S.V. , Smolyarchuk E.A.
ten
GUZ NO GKB No. 3 (NGTs)
Region
Nizhny Novgorod Region
Town
Nizhny Novgorod
Researchers
Makarova A.E
eleven
GBU RO "OKB"
Region
Ryazan Oblast
Town
Ryazan
Researchers
Ivanova A.Yu
12
SPb GBUZ "Nikolaevskaya hospital"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Nigrieva Y.N
thirteen
SPb GBUZ "City Mariinsky Hospital"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Mamonov A.G.
14
S-Pb GUZ "City Hospital No. 38 named after N. A. Semashko"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Popov A.V
15
SPb GBUZ "City Hospital No. 15"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Goloshchekin B.M
16
SPb GBUZ "City Pokrovskaya Hospital"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Khmelnitsky O.K
17
FGBOU VO Saratov State Medical University named after IN AND. Razumovsky Ministry of Health of Russia
Region
Saratov region
Town
Saratov
Researchers
Schwartz Yu.G
Next week could be a good week for our brokerage accounts here at IPIX.!
WOW! Huge NEWS! $IPIX
Protocol name
Double-blind, placebo-controlled, randomized, multicenter Phase II study to evaluate the efficacy and safety of Brilacidin in patients hospitalized with COVID-19
Therapeutic area
Anesthesiology and resuscitation, Infectious diseases, Oncology, Therapy (general), Surgery, Cardiology, Pulmonology, Toxicology
CI start and end date
12/17/2020 - 03/31/2021
RCT number and date
No. 705 dated 12/17/2020
CI organization
Innovation Pharmaceuticals Inc. (Innovation Pharmaceuticals Inc.)
Drug name
Brilacidin
Dosage form and dosage
solution for intravenous administration, 50 mg / ml
Cities
Barnaul, Kirovsk, Moscow, Nizhny Novgorod, Ryazan, St. Petersburg, Saratov, Yaroslavl
Developer country
USA
Organization involved by the drug developer
IPharma LLC, 143026, Moscow, the territory of the Skolkovo innovation center, st. Nobel, 7, Russia
CI phase
II
KI type
IMCI
The purpose of CI
assessment of the efficacy and safety of Brilacidin in patients hospitalized with COVID-19
Number of medical institutions
20
Number of patients
106
Where the research is done
one
KGBUZ "City Hospital No. 5, g. Barnaul "
Region
Altai region
Town
Barnaul
Researchers
Martynenko T.I.
2
GBUZ LO "Kirovskaya MB"
Region
Leningradskaya
Town
Kirovsk
Researchers
Klinov A.S
3
IKB No. 1
Region
Moscow city
Town
Moscow
Researchers
Nurmukhametova E.A.
four
GBUZ "GKB No. 52 DZM"
Region
Moscow city
Town
Moscow
Researchers
Fomina D.S
five
FSBI "Central Clinical Hospital with a Polyclinic"
Region
Moscow city
Town
Moscow
Researchers
Lomakin N.V.
6
GUZ GKB No. 15
Region
Moscow city
Town
Moscow
Researchers
Gordeev I.G.
7
FSBEI HE MGMSU them. A.I. Evdokimova, Ministry of Health of Russia
Region
Moscow city
Town
Moscow
Researchers
Vertkin A.L. , Rogova I.V.
8
GBUZ "NII SP named after N.V. Sklifosovsky Research Institute for Emergency Medicine "
Region
Moscow city
Town
Moscow
Researchers
Zhuravel S.V
9
FGAOU VO First MGMU im. THEM. Sechenov Moscow State Medical University (Sechenov University)
Region
Moscow city
Town
Moscow
Researchers
Moiseev S.V. , Smolyarchuk E.A.
ten
GUZ NO GKB No. 3 (NGTs)
Region
Nizhny Novgorod Region
Town
Nizhny Novgorod
Researchers
Makarova A.E
eleven
GBU RO "OKB"
Region
Ryazan Oblast
Town
Ryazan
Researchers
Ivanova A.Yu
12
SPb GBUZ "Nikolaevskaya hospital"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Nigrieva Y.N
thirteen
SPb GBUZ "City Mariinsky Hospital"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Mamonov A.G.
14
S-Pb GUZ "City Hospital No. 38 named after N. A. Semashko"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Popov A.V
15
SPb GBUZ "City Hospital No. 15"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Goloshchekin B.M
16
SPb GBUZ "City Pokrovskaya Hospital"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Khmelnitsky O.K
17
FGBOU VO Saratov State Medical University named after IN AND. Razumovsky Ministry of Health of Russia
Region
Saratov region
Town
Saratov
Researchers
Schwartz Yu.G
Pffft. It’s right up front bud.
FINRA short sales of IPIX in 3 - 2 - 1 -
If it can’t be right, then it must be wrong. Not.
Concentrations of 50mg/ml are not unheard of.
Nope. It will be diluted to the required dose and administered via IV.
50 mg/ml is high concentration.
WOW! Huge NEWS! $IPIX
Protocol name
Double-blind, placebo-controlled, randomized, multicenter Phase II study to evaluate the efficacy and safety of Brilacidin in patients hospitalized with COVID-19
Therapeutic area
Anesthesiology and resuscitation, Infectious diseases, Oncology, Therapy (general), Surgery, Cardiology, Pulmonology, Toxicology
CI start and end date
12/17/2020 - 03/31/2021
RCT number and date
No. 705 dated 12/17/2020
CI organization
Innovation Pharmaceuticals Inc. (Innovation Pharmaceuticals Inc.)
Drug name
Brilacidin
Dosage form and dosage
solution for intravenous administration, 50 mg / ml
Cities
Barnaul, Kirovsk, Moscow, Nizhny Novgorod, Ryazan, St. Petersburg, Saratov, Yaroslavl
Developer country
USA
Organization involved by the drug developer
IPharma LLC, 143026, Moscow, the territory of the Skolkovo innovation center, st. Nobel, 7, Russia
CI phase
II
KI type
IMCI
The purpose of CI
assessment of the efficacy and safety of Brilacidin in patients hospitalized with COVID-19
Number of medical institutions
20
Number of patients
106
Where the research is done
one
KGBUZ "City Hospital No. 5, g. Barnaul "
Region
Altai region
Town
Barnaul
Researchers
Martynenko T.I.
2
GBUZ LO "Kirovskaya MB"
Region
Leningradskaya
Town
Kirovsk
Researchers
Klinov A.S
3
IKB No. 1
Region
Moscow city
Town
Moscow
Researchers
Nurmukhametova E.A.
four
GBUZ "GKB No. 52 DZM"
Region
Moscow city
Town
Moscow
Researchers
Fomina D.S
five
FSBI "Central Clinical Hospital with a Polyclinic"
Region
Moscow city
Town
Moscow
Researchers
Lomakin N.V.
6
GUZ GKB No. 15
Region
Moscow city
Town
Moscow
Researchers
Gordeev I.G.
7
FSBEI HE MGMSU them. A.I. Evdokimova, Ministry of Health of Russia
Region
Moscow city
Town
Moscow
Researchers
Vertkin A.L. , Rogova I.V.
8
GBUZ "NII SP named after N.V. Sklifosovsky Research Institute for Emergency Medicine "
Region
Moscow city
Town
Moscow
Researchers
Zhuravel S.V
9
FGAOU VO First MGMU im. THEM. Sechenov Moscow State Medical University (Sechenov University)
Region
Moscow city
Town
Moscow
Researchers
Moiseev S.V. , Smolyarchuk E.A.
ten
GUZ NO GKB No. 3 (NGTs)
Region
Nizhny Novgorod Region
Town
Nizhny Novgorod
Researchers
Makarova A.E
eleven
GBU RO "OKB"
Region
Ryazan Oblast
Town
Ryazan
Researchers
Ivanova A.Yu
12
SPb GBUZ "Nikolaevskaya hospital"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Nigrieva Y.N
thirteen
SPb GBUZ "City Mariinsky Hospital"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Mamonov A.G.
14
S-Pb GUZ "City Hospital No. 38 named after N. A. Semashko"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Popov A.V
15
SPb GBUZ "City Hospital No. 15"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Goloshchekin B.M
16
SPb GBUZ "City Pokrovskaya Hospital"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Khmelnitsky O.K
17
FGBOU VO Saratov State Medical University named after IN AND. Razumovsky Ministry of Health of Russia
Region
Saratov region
Town
Saratov
Researchers
Schwartz Yu.G $IPIX
Protocol name
Double-blind, placebo-controlled, randomized, multicenter Phase II study to evaluate the efficacy and safety of Brilacidin in patients hospitalized with COVID-19
Therapeutic area
Anesthesiology and resuscitation, Infectious diseases, Oncology, Therapy (general), Surgery, Cardiology, Pulmonology, Toxicology
CI start and end date
12/17/2020 - 03/31/2021
RCT number and date
No. 705 dated 12/17/2020
CI organization
Innovation Pharmaceuticals Inc. (Innovation Pharmaceuticals Inc.)
Drug name
Brilacidin
Dosage form and dosage
solution for intravenous administration, 50 mg / ml
Cities
Barnaul, Kirovsk, Moscow, Nizhny Novgorod, Ryazan, St. Petersburg, Saratov, Yaroslavl
Developer country
USA
Organization involved by the drug developer
IPharma LLC, 143026, Moscow, the territory of the Skolkovo innovation center, st. Nobel, 7, Russia
CI phase
II
KI type
IMCI
The purpose of CI
assessment of the efficacy and safety of Brilacidin in patients hospitalized with COVID-19
Number of medical institutions
20
Number of patients
106
Where the research is done
one
KGBUZ "City Hospital No. 5, g. Barnaul "
Region
Altai region
Town
Barnaul
Researchers
Martynenko T.I.
2
GBUZ LO "Kirovskaya MB"
Region
Leningradskaya
Town
Kirovsk
Researchers
Klinov A.S
3
IKB No. 1
Region
Moscow city
Town
Moscow
Researchers
Nurmukhametova E.A.
four
GBUZ "GKB No. 52 DZM"
Region
Moscow city
Town
Moscow
Researchers
Fomina D.S
five
FSBI "Central Clinical Hospital with a Polyclinic"
Region
Moscow city
Town
Moscow
Researchers
Lomakin N.V.
6
GUZ GKB No. 15
Region
Moscow city
Town
Moscow
Researchers
Gordeev I.G.
7
FSBEI HE MGMSU them. A.I. Evdokimova, Ministry of Health of Russia
Region
Moscow city
Town
Moscow
Researchers
Vertkin A.L. , Rogova I.V.
8
GBUZ "NII SP named after N.V. Sklifosovsky Research Institute for Emergency Medicine "
Region
Moscow city
Town
Moscow
Researchers
Zhuravel S.V
9
FGAOU VO First MGMU im. THEM. Sechenov Moscow State Medical University (Sechenov University)
Region
Moscow city
Town
Moscow
Researchers
Moiseev S.V. , Smolyarchuk E.A.
ten
GUZ NO GKB No. 3 (NGTs)
Region
Nizhny Novgorod Region
Town
Nizhny Novgorod
Researchers
Makarova A.E
eleven
GBU RO "OKB"
Region
Ryazan Oblast
Town
Ryazan
Researchers
Ivanova A.Yu
12
SPb GBUZ "Nikolaevskaya hospital"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Nigrieva Y.N
thirteen
SPb GBUZ "City Mariinsky Hospital"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Mamonov A.G.
14
S-Pb GUZ "City Hospital No. 38 named after N. A. Semashko"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Popov A.V
15
SPb GBUZ "City Hospital No. 15"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Goloshchekin B.M
16
SPb GBUZ "City Pokrovskaya Hospital"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Khmelnitsky O.K
17
FGBOU VO Saratov State Medical University named after IN AND. Razumovsky Ministry of Health of Russia
Region
Saratov region
Town
Saratov
Researchers
Schwartz Yu.G
Not everyone is missing the point.!
Hope all is well.
Hound.
Ready for $2 break! Let's go!
FFS. How the hell can I bash this ipix shit if it’s all in Russian! Bossman, you gotta move me to another ticker or get a Russian translator in here stat or I QUIT!
WOW! Huge NEWS! $IPIX
Protocol name
Double-blind, placebo-controlled, randomized, multicenter Phase II study to evaluate the efficacy and safety of Brilacidin in patients hospitalized with COVID-19
Therapeutic area
Anesthesiology and resuscitation, Infectious diseases, Oncology, Therapy (general), Surgery, Cardiology, Pulmonology, Toxicology
CI start and end date
12/17/2020 - 03/31/2021
RCT number and date
No. 705 dated 12/17/2020
CI organization
Innovation Pharmaceuticals Inc. (Innovation Pharmaceuticals Inc.)
Drug name
Brilacidin
Dosage form and dosage
solution for intravenous administration, 50 mg / ml
Cities
Barnaul, Kirovsk, Moscow, Nizhny Novgorod, Ryazan, St. Petersburg, Saratov, Yaroslavl
Developer country
USA
Organization involved by the drug developer
IPharma LLC, 143026, Moscow, the territory of the Skolkovo innovation center, st. Nobel, 7, Russia
CI phase
II
KI type
IMCI
The purpose of CI
assessment of the efficacy and safety of Brilacidin in patients hospitalized with COVID-19
Number of medical institutions
20
Number of patients
106
Where the research is done
one
KGBUZ "City Hospital No. 5, g. Barnaul "
Region
Altai region
Town
Barnaul
Researchers
Martynenko T.I.
2
GBUZ LO "Kirovskaya MB"
Region
Leningradskaya
Town
Kirovsk
Researchers
Klinov A.S
3
IKB No. 1
Region
Moscow city
Town
Moscow
Researchers
Nurmukhametova E.A.
four
GBUZ "GKB No. 52 DZM"
Region
Moscow city
Town
Moscow
Researchers
Fomina D.S
five
FSBI "Central Clinical Hospital with a Polyclinic"
Region
Moscow city
Town
Moscow
Researchers
Lomakin N.V.
6
GUZ GKB No. 15
Region
Moscow city
Town
Moscow
Researchers
Gordeev I.G.
7
FSBEI HE MGMSU them. A.I. Evdokimova, Ministry of Health of Russia
Region
Moscow city
Town
Moscow
Researchers
Vertkin A.L. , Rogova I.V.
8
GBUZ "NII SP named after N.V. Sklifosovsky Research Institute for Emergency Medicine "
Region
Moscow city
Town
Moscow
Researchers
Zhuravel S.V
9
FGAOU VO First MGMU im. THEM. Sechenov Moscow State Medical University (Sechenov University)
Region
Moscow city
Town
Moscow
Researchers
Moiseev S.V. , Smolyarchuk E.A.
ten
GUZ NO GKB No. 3 (NGTs)
Region
Nizhny Novgorod Region
Town
Nizhny Novgorod
Researchers
Makarova A.E
eleven
GBU RO "OKB"
Region
Ryazan Oblast
Town
Ryazan
Researchers
Ivanova A.Yu
12
SPb GBUZ "Nikolaevskaya hospital"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Nigrieva Y.N
thirteen
SPb GBUZ "City Mariinsky Hospital"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Mamonov A.G.
14
S-Pb GUZ "City Hospital No. 38 named after N. A. Semashko"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Popov A.V
15
SPb GBUZ "City Hospital No. 15"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Goloshchekin B.M
16
SPb GBUZ "City Pokrovskaya Hospital"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Khmelnitsky O.K
17
FGBOU VO Saratov State Medical University named after IN AND. Razumovsky Ministry of Health of Russia
Region
Saratov region
Town
Saratov
Researchers
Schwartz Yu.G $IPIX
Protocol name
Double-blind, placebo-controlled, randomized, multicenter Phase II study to evaluate the efficacy and safety of Brilacidin in patients hospitalized with COVID-19
Therapeutic area
Anesthesiology and resuscitation, Infectious diseases, Oncology, Therapy (general), Surgery, Cardiology, Pulmonology, Toxicology
CI start and end date
12/17/2020 - 03/31/2021
RCT number and date
No. 705 dated 12/17/2020
CI organization
Innovation Pharmaceuticals Inc. (Innovation Pharmaceuticals Inc.)
Drug name
Brilacidin
Dosage form and dosage
solution for intravenous administration, 50 mg / ml
Cities
Barnaul, Kirovsk, Moscow, Nizhny Novgorod, Ryazan, St. Petersburg, Saratov, Yaroslavl
Developer country
USA
Organization involved by the drug developer
IPharma LLC, 143026, Moscow, the territory of the Skolkovo innovation center, st. Nobel, 7, Russia
CI phase
II
KI type
IMCI
The purpose of CI
assessment of the efficacy and safety of Brilacidin in patients hospitalized with COVID-19
Number of medical institutions
20
Number of patients
106
Where the research is done
one
KGBUZ "City Hospital No. 5, g. Barnaul "
Region
Altai region
Town
Barnaul
Researchers
Martynenko T.I.
2
GBUZ LO "Kirovskaya MB"
Region
Leningradskaya
Town
Kirovsk
Researchers
Klinov A.S
3
IKB No. 1
Region
Moscow city
Town
Moscow
Researchers
Nurmukhametova E.A.
four
GBUZ "GKB No. 52 DZM"
Region
Moscow city
Town
Moscow
Researchers
Fomina D.S
five
FSBI "Central Clinical Hospital with a Polyclinic"
Region
Moscow city
Town
Moscow
Researchers
Lomakin N.V.
6
GUZ GKB No. 15
Region
Moscow city
Town
Moscow
Researchers
Gordeev I.G.
7
FSBEI HE MGMSU them. A.I. Evdokimova, Ministry of Health of Russia
Region
Moscow city
Town
Moscow
Researchers
Vertkin A.L. , Rogova I.V.
8
GBUZ "NII SP named after N.V. Sklifosovsky Research Institute for Emergency Medicine "
Region
Moscow city
Town
Moscow
Researchers
Zhuravel S.V
9
FGAOU VO First MGMU im. THEM. Sechenov Moscow State Medical University (Sechenov University)
Region
Moscow city
Town
Moscow
Researchers
Moiseev S.V. , Smolyarchuk E.A.
ten
GUZ NO GKB No. 3 (NGTs)
Region
Nizhny Novgorod Region
Town
Nizhny Novgorod
Researchers
Makarova A.E
eleven
GBU RO "OKB"
Region
Ryazan Oblast
Town
Ryazan
Researchers
Ivanova A.Yu
12
SPb GBUZ "Nikolaevskaya hospital"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Nigrieva Y.N
thirteen
SPb GBUZ "City Mariinsky Hospital"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Mamonov A.G.
14
S-Pb GUZ "City Hospital No. 38 named after N. A. Semashko"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Popov A.V
15
SPb GBUZ "City Hospital No. 15"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Goloshchekin B.M
16
SPb GBUZ "City Pokrovskaya Hospital"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Khmelnitsky O.K
17
FGBOU VO Saratov State Medical University named after IN AND. Razumovsky Ministry of Health of Russia
Region
Saratov region
Town
Saratov
Researchers
Schwartz Yu.G
WOW Huge NEWS! $IPIX
Did someone say RALLY! $IPIX
Will we see the RALLY MONKEY today...
Breakfast is wrapping up. Looking to add more on the dip!
Looking to add more on the dip.!
Me too! Lower the better.!
I’m buying!
I see a gap up, a run, and 20,978,229 more reasons the gap will fill!
Yep - definitely a better class of accommodation address.
Correct. Same person. I’m ready for the PR and the gap up!